Nexus Pharmaceuticals unveils Erythromycin Lactobionate for Injection, USP in 500mg/vial
22 April 2022 -

Nexus Pharmaceuticals reported on Thursday the availability of Erythromycin Lactobionate for Injection, USP in 500mg/vial in single-dose vials for the treatment of infections caused by susceptible strains of designated organisms when oral administration is not possible or when the severity of the infection requires immediate high serum levels of erythromycin.

The company added that the Erythromycin Lactobionate for Injection is available in cartons of five single-dose vials and is an AP-rated generic to ERYTHROCIN¥.

In addition, the launch of Erythromycin Lactobionate showcases the company's commitment to providing critical antibiotics where and when they are needed most, said Vince LoPiccolo, VP of Sales and Marketing.

Based in the US, the healthcare company specialises in innovative processes to make difficult-to-manufacture specialty and generic drugs that are easier to use, less labor-intensive, and more streamlined in practice.